Introduction to “The ANDA Review Pathway” (11/28) Generic Drugs Forum 2017

Tom Hinchliffe, CDER Office of Generic Drugs, discusses how a drug moves though the abbreviated new drug application (ANDA) review pathway.
_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.

Phone: [phone] I [phone]